Composition, form of production and packaging
Solution for infusions is transparent, colorless or slightly yellowish, odorless.
dextran with a molecular weight of 30 000 to 50 000 10 g
mannitol 5 g
Sodium Chloride 900 mg
[PRING] water d / and up to 100 ml.
400 ml - bottles for blood substitutes.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2005.
Plasmo-replacing drug. Reduces the viscosity of blood by reducing the aggregation of blood cells, helps restore blood flow in small capillaries. It also has anti-shock, detoxification and diuretic effect.
1 g of dextran, which is part of Reogluman, promotes the passage of 20-25 ml of liquid from the tissue into the bloodstream.
The drug is excreted from the body, mainly with urine: for the first day, approximately 70%. The rest of the drug enters the reticuloendothelial system, where it gradually becomes biotransformed to glucose.
Prevention and treatment of diseases accompanied by violations of microcirculation, both local and general, combined with fluid retention in the body:
- violation of capillary blood flow (traumatic, burn, toxic, cardiogenic shock);
- violation of arterial and venous circulation (thrombosis, thrombophlebitis, endarteritis, Raynaud's disease);
- in vascular and plastic surgery (to improve local circulation and reduce the tendency to thrombosis in the transplant);
renal and renal-hepatic insufficiency with preserved filtration function of the kidneys;
- Post-transfusion complications caused by transfusion of incompatible blood;
- for detoxification with burns, injuries, peritonitis, pancreatitis.
Reogluman injected intravenously into the drip (IV injection can lead to hypervolemia due to the expressed colloid-osmotic effect of the drug). Doses and the speed of administration of the drug are set individually in accordance with the indications, assessment of the patient's condition and his hourly and daily diuresis.
In complex therapy of shock in case of capillary blood flow disturbance, the drug is administered at a dose of 400 to 800 ml under the control of hemodynamic parameters (blood pressure and CVP, bcc, hourly and daily diuresis).
In case of burn shock , a 2-3-fold administration of the drug within the first 24 hours from the moment of injury is permissible. The first dose of the drug 400 ml can be administered within 2 hours, the second - after 6-12 hours with the same infusion rate. If other dextran preparations (polyglucin, reopolyglucin) are used, their total dose should not exceed 1600 mg / day (100-130 g of dextran). During the second day of the shock period with stabilization of bcc, blood pressure and diuresis, the drug is administered 400 ml 1-2 times.
In the period of acute burn toxemia, Reogluman can be applied daily or every other day through 400 ml as part of a combined infusion therapy, with mandatory control of diurnal diuresis, hemoglobin and hematocrit.
During septicotoxemia, the use of Reogluman in the same doses is most expedient when preparing a patient for autodermoplasty and for the first 2 days from the moment of its implementation.
In cardiovascular and plastic surgery, Reogluman is administered immediately before the operation (30-60 min) at a dose of 10 ml / kg of body weight, during operation 400 ml and after surgery daily for 5-6 days at a rate of 10 ml / kg of body weight body for a single injection.
In acute renal and hepatic insufficiency with preserved filtration and with post-transfusion complications, Reogluman is administered once in a dose of 400-800 ml.The infusion of the drug can be repeated daily for 3-5 days, at a rate of 10 ml / kg of body weight for administration under the control of water-electrolyte and acid-base balance and coagulation system of blood.
Allergic reactions: in some cases (in previously sensitized patients), allergic reactions of varying severity may occur; anaphylactic shock may occur (in patients with a history of intolerance to IV infusions of protein preparations, plasma substitutes (including dextran preparations), and sera, vaccines).
From the cardiovascular system: tachycardia, lowering blood pressure.
- excessive hemodilution (hematocrit below 25 units);
-chronic heart failure with pronounced edema;
- Severe renal failure accompanied by anuria;
- Significant dehydration of the patient;
Severe allergic conditions of unclear etiology.
PREGNANCY AND LACTATION
Data on the efficacy and safety of the use of the drug Reogluman during pregnancy and lactation are not provided.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated in severe kidney failure, accompanied by anuria.
When using Reoglumana, a biological test is mandatory: after a slow IV injection of the first 5 drops of the drug, the infusion is stopped for 3 minutes, then another 30 drops are added and the infusion is again stopped for 3 minutes. In the absence of a reaction, the administration of the drug continues.
In case of allergic reactions or complications, the infusion should be stopped immediately and, without taking the needles out of the vein, enter symptomatic medicines used in the therapy of anaphylactic shock (antihistamines, GCS, vasoconstrictors and other drugs).
To maintain the water and electrolyte balance, together with Reogluman, it is advisable to introduce solutions containing potassium and sodium.
Before the introduction of Reoglumana, a visual inspection of the drug should be performed. The drug should be clear, free from suspensions, there should be no cracks or seals on the vial.
Data on the overdose of the drug Reogluman are not provided.
Reogluman is compatible with other dextran preparations (polyglucin, reopolyglucin) and crystalloid solutions.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry place at a temperature of no higher than 25 В° C. Freezing during transportation is allowed. Shelf life - 3 years.